Equity research analysts expect ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Rating) to post earnings per share of $0.08 for the current quarter, Zacks reports. Two analysts provided earnings estimates for ANI Pharmaceuticals. ANI Pharmaceuticals reported earnings per share of $1.04 in the same quarter last year, suggesting a negative year-over-year growth rate of 92.3%. The company is expected to announce its next quarterly results before the market opens on Monday, January 1.
According to Zacks, analysts expect ANI Pharmaceuticals to report annual earnings of $1.15 per share for the current fiscal year, with EPS estimates ranging from $1.11 to $1.22. For next year, analysts expect the company to post earnings of $2.70 per share, with EPS estimates ranging from $2.62 to $2.78. Zacks Investment Research earnings per share averages are an average based on a survey of research analysts who cover ANI Pharmaceuticals.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) last reported quarterly earnings data on Tuesday, March 15. The specialty pharmaceutical company reported earnings per share (EPS) of $0.38 for the quarter, missing consensus analyst estimates of $0.69 per ($0.31). ANI Pharmaceuticals recorded a negative net margin of 19.71% and a positive return on equity of 14.10%. The company posted revenue of $60.93 million in the quarter, versus a consensus estimate of $58.25 million. In the same quarter a year earlier, the company posted earnings of $0.65 per share.
ANIP has been the subject of several research reports. StockNews.com downgraded ANI Pharmaceuticals from a “Hold” rating to a “Sell” rating in a Wednesday, April 27 research note. Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a Monday, March 14 report. TheStreet downgraded ANI Pharmaceuticals from a “c-” rating to a “d+” rating in a Wednesday, March 30 report. Cantor Fitzgerald reaffirmed a “neutral” rating on ANI Pharmaceuticals shares in a Wednesday, March 16 research report. Finally, Raymond James lowered his price target on ANI Pharmaceuticals from $65.00 to $47.00 and set an “outperform” rating on the stock in a Wednesday, March 16 research report. One research analyst rated the stock with a sell rating, two assigned a hold rating and two assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $56.67.
Separately, director Patrick D. Walsh purchased 5,000 shares of the company in a transaction that took place on Monday, March 21. The shares were purchased at an average price of $27.76 per share, for a total transaction of $138,800.00. The transaction was disclosed in a legal filing with the SEC, accessible via the SEC’s website. Additionally, CEO Nikhil Lalwani acquired 7,224 shares in a transaction on Monday, March 21. The shares were acquired at an average cost of $27.69 per share, for a total transaction of $200,032.56. Disclosure of this purchase can be found here. Over the past ninety days, insiders have purchased 17,224 shares of the company valued at $477,083. Insiders hold 27.20% of the shares of the company.
A number of institutional investors and hedge funds have recently changed their holdings in the company. Parkman Healthcare Partners LLC increased its stake in ANI Pharmaceuticals by 54.2% during the third quarter. Parkman Healthcare Partners LLC now owns 85,346 shares of the specialty pharmaceutical company worth $2,801,000 after acquiring an additional 30,000 shares during the period. Emerald Mutual Fund Advisers Trust acquired a new equity stake in ANI Pharmaceuticals during Q4, valued at $4,124,000. Allspring Global Investments Holdings LLC bought a new position in ANI Pharmaceuticals stock during Q4 worth $196,000. Collective Family Office LLC bought a new position in ANI Pharmaceuticals in Q4 worth $241,000. Finally, Deutsche Bank AG increased its stake in ANI Pharmaceuticals by 45.1% in the third quarter. Deutsche Bank AG now owns 192,474 shares of the specialty pharmaceutical company worth $6,317,000 after acquiring an additional 59,862 shares during the period. Institutional investors hold 59.66% of the company’s shares.
Shares of ANIP traded down $0.86 in Friday’s midday session, hitting $27.42. 120,177 shares of the company were traded, against an average volume of 94,268. ANI Pharmaceuticals has a one-year low of $24.41 and a one-year high of $60.23. The company has a debt ratio of 0.86, a current ratio of 3.68 and a quick ratio of 2.74. The company has a market capitalization of $473.54 million, a P/E ratio of -8.44 and a beta of 1.06. The stock has a 50-day moving average of $30.96 and a 200-day moving average of $38.77.
About ANI Pharmaceuticals (Get a rating)
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures and markets branded and generic prescription pharmaceutical products in the United States and Canada. It focuses on the production of controlled substances, oncology products, hormones and steroids, injectables and other formulations. The company manufactures solid oral dose products; semi-solids, liquids and topicals; and potency products, as well as the development and contract manufacturing of pharmaceutical products for other companies.
Get a Free Copy of Zacks Research Report on ANI Pharmaceuticals (ANIP)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for ANI Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for ANI Pharmaceuticals and related companies with MarketBeat.com’s FREE daily newsletter.